M. Bissery

发表

Experimental chronotherapy of mouse mammary adenocarcinoma MA13/C with docetaxel and doxorubicin as single agents and in combination.

P. Vrignaud, F. Lévi, T. Granda, 2001, Cancer research.

From Random Screening of Chemical Libraries to the Optimization of FPP-Competitive Inhibitors of Farnesyltransferase

P. Vrignaud, M. Bissery, J. Riou, 2001 .

Early Quantitative Evaluation of a Tumor Vasculature Disruptive Agent AVE8062 Using Dynamic Contrast-Enhanced Ultrasonography

P. Vrignaud, S. Koscielny, N. Lassau, 2008, Investigative radiology.

Combined effects of docetaxel and angiostatin gene therapy in prostate tumor model.

David Opolon, P. Opolon, Hong Li, 2003, Molecular therapy : the journal of the American Society of Gene Therapy.

Interaction between flavone acetic acid (LM-975, NSC 349512) and radiation in Glasgow's osteogenic sarcoma in vivo.

W. De Neve, J. Evelhoch, F. Valeriote, 1990, International Journal of Radiation Oncology, Biology, Physics.

Docetaxel chronopharmacology in mice.

P. Vrignaud, F. Lévi, E. Filipski, 1998, Cancer research.

Experimental antitumor activity and pharmacokinetics of the camptothecin analog irinotecan (CPT-11) in mice

P. Vrignaud, M. Bissery, G. Chabot, 1996, Anti-cancer drugs.

GTL001 and bivalent CyaA-based therapeutic vaccine strategies against human papillomavirus and other tumor-associated antigens induce effector and memory T-cell responses that inhibit tumor growth.

M. Bissery, A. Goubier, Michael Esquerré, 2017, Vaccine.

Docetaxel (Taxotere): a review of preclinical and clinical experience. Part I: Preclinical experience.

M. Bissery, G. Nohynek, G. Sanderink, 1995, Anti-cancer drugs.

Evaluation of Microtubule Associated Parameters (MTAPs) as predictive markers for Advanced Breast Cancer (ABC) patients treated with docetaxel

D. Larsimont, M. Piccart, F. Cardoso, 2001 .

Syntheses and structure-activity relationships of the second-generation antitumor taxoids: exceptional activity against drug-resistant cancer cells.

P. Vrignaud, S. Kuduk, J. Veith, 1996, Journal of medicinal chemistry.

antitumor combinations containing Vegt inhibitor agent and a 5-FU or its derivatives

P. Vrignaud, J. Cedarbaum, E. Furfine, 2004 .

Microtubule-associated parameters as predictive markers of docetaxel activity in advanced breast cancer patients: results of a pilot study.

D. Larsimont, M. Piccart, F. Cardoso, 2002, Clinical breast cancer.

Preclinical Antitumor Activity and Pharmacokinetics of Irinotecan (CPT‐11) in Tumor‐bearing Mice

P. Vrignaud, M. Bissery, G. Chabot, 1996, Annals of the New York Academy of Sciences.

Response of human tumor xenografts in athymic nude mice to docetaxel (RP 56976, Taxotere®)

M. Bissery, W. Waud, D. Dykes, 2007, Investigational New Drugs.

Preclinical Antitumor Activity of Cabazitaxel, a Semisynthetic Taxane Active in Taxane-Resistant Tumors

P. Vrignaud, M. Bissery, J. Riou, 2013, Clinical Cancer Research.

Pharmacodynamics and causes of dose-dependent pharmacokinetics of flavone-8-acetic acid (LM-975; NSC-347512) in mice

L. Baker, M. Bissery, K. Rutkowski, 2004, Cancer Chemotherapy and Pharmacology.

Influence of tumor size on the main drug-metabolizing enzyme systems in mouse colon adenocarcinoma Co38

S. Koscielny, M. Bissery, J. Morizet, 2004, Cancer Chemotherapy and Pharmacology.

Activity of batracylin (NSC-320846) against solid tumors of mice

F. Valeriote, J. Plowman, M. Bissery, 1989, Investigational New Drugs.

Evaluation of tissue perfusion (tumor, spleen, heart) in mice after administration of AVE8062, a tumor vascular-targeting agent

P. Vrignaud, M. Bissery, M. Guffroy, 2004 .

Preclinical evaluation of CPT-11 and its active metabolite SN-38.

F. Roquet, M. Bissery, J. Riou, 1996, Seminars in oncology.

Discovery of Solid Tumor Active Agents Using a Soft-Agar-Colony-Formation Disk-Diffusion-Assay

A. Wozniak, P. LoRusso, F. Valeriote, 1992 .

Effects of Taxotere and taxol on in vitro colony formation of freshly explanted human tumor cells

S. Hilsenbeck, D. V. Von Hoff, S. Hilsenbeck, 1992, Anti-cancer drugs.

Flavone acetic acid (LM-975; NSC-347512) activation to cytotoxic species in vivo and in vitro

M. Bissery, A. Gouyette, G. Chabot, 2004, Cancer Chemotherapy and Pharmacology.

Potent therapeutic activity of irinotecan (CPT‐11) and its schedule dependency in medulloblastoma xenografts in nude mice

C. Sainte-Rose, G. Vassal, M. Bissery, 1997, International journal of cancer.

Preclinical profile of docetaxel (taxotere): efficacy as a single agent and in combination.

P. Vrignaud, M. Bissery, F. Lavelle, 1995, Seminars in oncology.

Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against human tumor xenografts: lack of cross-resistance in vivo in tumors with acquired resistance to the topoisomerase I inhibitor 9-dimethylaminomethyl-10-hydroxycamptothecin.

P. Houghton, J. Houghton, M. Bissery, 1993, Cancer research.

Experimental antitumor activity of taxotere (RP 56976, NSC 628503), a taxol analogue.

M. Bissery, D. Guénard, F. Lavelle, 1991, Cancer research.

Preclinical activity of taxotere (RP 56976, NSC 628503) against freshly explanted clonogenic human tumour cells: comparison with taxol and conventional antineoplastic agents.

C. Fellbaum, M. Aapro, H. Nekarda, 1993, European journal of cancer.

The mechanism of action of docetaxel (Taxotere®) in xenograft models is not limited to bcl-2 phosphorylation

M. Bissery, W. Waud, S. Schmid, 2003, Investigational New Drugs.

Preclinical antitumor activity of CI-994

P. LoRusso, W. Leopold, M. Bissery, 2004, Investigational New Drugs.

Tumor Models and the Discovery and Secondary Evaluation of Solid Tumor Active Agents

J. M. Shaw, A. Wozniak, P. LoRusso, 1995 .

GTL001, A Therapeutic Vaccine for Women Infected with Human Papillomavirus 16 or 18 and Normal Cervical Cytology: Results of a Phase I Clinical Trial

H. Goossens, P. van Damme, M. Bissery, 2016, Clinical Cancer Research.

Therapeutic activity of CPT-11, a DNA-topoisomerase I inhibitor, against peripheral primitive neuroectodermal tumour and neuroblastoma xenografts.

G. Vassal, M. Bissery, J. Morizet, 1996, British Journal of Cancer.

Class III β-Tubulin Isotype Predicts Response in Advanced Breast Cancer Patients Randomly Treated Either with Single-Agent Doxorubicin or Docetaxel

D. Larsimont, M. Piccart, F. Cardoso, 2008, Clinical Cancer Research.

Antitumor activity of intoplicine (RP 60475, NSC 645008), a new benzo-pyrido-indole: evaluation against solid tumors and leukemias in mice

P. Vrignaud, C. Nguyen, M. Bissery, 1993, Investigational New Drugs.

GTL001, a bivalent therapeutic vaccine against human papillomavirus 16 and 18, induces antigen-specific CD8+ T cell responses leading to tumor regression

M. Bissery, A. Goubier, Michael Esquerré, 2017, PloS one.

GTL 001 , A Therapeutic Vaccine for Women Infected with Human Papillomavirus 16 or 18 and Normal Cervical Cytology : Results of a Phase I Clinical Trial

H. Goossens, M. Bissery, B. Timmerman, 2016 .

Preclinical pharmacology of docetaxel.

M. Bissery, 1995, European journal of cancer.

Preclinical Pharmacology and Phase I Clinical Trials of Taxotere R (RP 56976, NSC 628503)

R. Pazdur, H. Burris, M. Bissery, 1994 .

5-Fluorouracil containing combinations in murine tumor systems

M. Bissery, T. Corbett, L. Polin, 1989, Investigational New Drugs.

Activity of flavone acetic acid (NSC-347512) against solid tumors of mice

A. Wozniak, F. Valeriote, J. Plowman, 2004, Investigational New Drugs.

Preclinical Antitumor Efficacy of Taxotere (RP56976, NSC 628503), a Taxol Analog and of RP60475 (NSC645008), a New Benzopyridoindole

M. Bissery, F. Lavelle, 1992 .

Phase I dose-finding and pharmacokinetic study of docetaxel and vinorelbine as first-line chemotherapy for metastatic breast cancer.

M. Campone, P. Fumoleau, M. Bissery, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

Superior Antitumor Activity of SAR3419 to Rituximab in Xenograft Models for Non-Hodgkin's Lymphoma

R. Mohammad, A. Al-Katib, M. Bissery, 2009, Clinical Cancer Research.

Cancer Therapy : Preclinical Superior Antitumor Activity of SAR 3419 to Rituximab in Xenograft Models for Non-Hodgkin ' s Lymphoma

R. Mohammad, A. Al-Katib, M. Bissery, 2009 .

Preclinical evaluation of new taxoids.

M. Bissery, 2001, Current pharmaceutical design.

Activity of intoplicine (RP60475), a new DNA topoisomerase I and II inhibitor, against human tumor colony-forming units in vitro.

D. V. Von Hoff, G. Clark, H. Burris, 1994, Journal of the National Cancer Institute.

525 POSTER Preclinical evaluation of SAR566658 (huDS6-DM4) in mice bearing human tumor xenografts of breast, ovarian, lung, cervical and pancreatic cancer

P. Vrignaud, R. Lutz, V. Blanc, 2008 .

Circadian optimisation of irinotecan and oxaliplatin efficacy in mice with Glasgow osteosarcoma

P. Vrignaud, F. Lévi, T. Granda, 2002, British Journal of Cancer.

130 Preclinical results of ProCervix, a first in class, first in indication therapeutic vaccine targeting HPV16/18 infected women

M. Bissery, A. Goubier, Michael Esquerré, 2014 .

Superior Anti-Tumor Activity of the CD19-Directed Immunotoxin, SAR3419 to Rituximab in Non-Hodgkin’s Xenograft Animal Models: Preclinical Evaluation.

R. Mohammad, A. Al-Katib, A. Goustin, 2007 .

In vivo synergy between trastuzumab (herceptin ® ) and larotaxel (RPR 109881A), a new taxoid.

P. Vrignaud, M. Chiron, M. Bissery, 2007 .

In vivo synergy between doxorubicin, cisplatin or vinorelbine and RPR 109881A, a new taxoid

P. Vrignaud, M. Bissery, P. Lejeune, 2005 .

Preclinical evaluation of docetaxel (Taxotere).

P. Vrignaud, M. Bissery, J. Riou, 1995, Seminars in oncology.

Combination of the antiangiogenic agent aflibercept (VEGF Trap) with docetaxel or gemcitabine results in greater antitumor activity in tumor bearing mice.

P. Vrignaud, M. Chiron, M. Bissery, 2008 .

Synergistic activity of aflibercept (VEGF Trap) in combination with 5-fluorouracil and irinotecan in preclinical tumor models

P. Vrignaud, W. Leopold, M. Chiron, 2007 .

Can taxanes provide benefit in patients with CNS tumors and in pediatric patients with tumors? An update on the preclinical development of cabazitaxel

P. Vrignaud, S. Sidhu, M. Bissery, 2013, Cancer Chemotherapy and Pharmacology.

GTL001 and bivalent CyaA-based therapeutic vaccine strategies against human papillomavirus and other tumor-associated antigens induce effector and memory T-cell responses that inhibit tumor growth.

M. Bissery, A. Goubier, Michael Esquerré, 2017, Vaccine.